Clinical Trials DEA Legalization Policy 
The Cannigma
JUNE 14, 2021
All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We Junk’ cannabis ‘ill-suited for clinical trials’. BRC) told The Cannigma this week.
NORML
MARCH 1, 2019
In August 2016, the US Drug Enforcement Administration announced in the US Federal Register that the agency was “adopting a new policy that is designed to increase the number of entities registered under the Controlled Substances Act to grow (manufacture) marijuana to supply legitimate researchers in the United States.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
FEBRUARY 10, 2022
Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.
Veriheal
JUNE 30, 2023
A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.
Cannabis Law Report
OCTOBER 4, 2021
A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. However, this drug is not presently legally available, as it is classified as a Schedule I drug, severely restricted and regulated by the federal Controlled Substances Act.
Cannabis Law Report
MAY 29, 2022
In 2020, Oregon became the first locale to decriminalize psilocybin and legalize it for therapeutic use on a statewide basis. 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. Clinical Trials and Human Subject Protections. DEA and the Controlled Substances Act.
Cannabis Law Report
FEBRUARY 28, 2022
Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. This Essay analyzes the ethical, legal, and social implications of patenting these controversial substances. Trial of Psilocybin Versus Escitalopram for Depression , 384 NEW ENG. Mitchell et al.,
Expert insights. Personalized for you.
133 
Let's personalize your content